Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Neyns

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 2009
Stratified phase II trial of cetuximab in patients with recurrent high-grade gliomaB Neyns, J Sadones, E Joosens, et al.
Journal of Neuro-Oncology|March 4, 2016
Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastomaJ Duerinck, S Du Four, F Vandervorst, et al.
Journal of Neuro-Oncology|October 9, 2017
Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastomaJ Duerinck, S Du Four, F Bouttens, et al.
Breast (Edinburgh, Scotland)|May 6, 2008
Tolerance of adjuvant letrozole outside of clinical trialsC Fontaine, A Meulemans, M Huizing, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 6, 2007
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapyE Van Cutsem, S Siena, Y Humblet, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 23, 2020
The predictive and prognostic significance of cell-free DNA concentration in melanomaR Váraljai, S Elouali, S S Lueong, et al.
European Journal of Cancer (Oxford, England : 1990)|October 24, 2008
MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastomaJ Sadones, A Michotte, P Veld, et al.
ESMO Open|February 15, 2025
Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028M Donia, H Jespersen, M Jalving, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 28, 2022
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142T André, S Lonardi, K Y M Wong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2021
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006G V Long, A Arance, L Mortier, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 2009
Stratified phase II trial of cetuximab in patients with recurrent high-grade gliomaB Neyns, J Sadones, E Joosens, et al.
Journal of Neuro-Oncology|March 4, 2016
Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastomaJ Duerinck, S Du Four, F Vandervorst, et al.
Journal of Neuro-Oncology|October 9, 2017
Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastomaJ Duerinck, S Du Four, F Bouttens, et al.
Breast (Edinburgh, Scotland)|May 6, 2008
Tolerance of adjuvant letrozole outside of clinical trialsC Fontaine, A Meulemans, M Huizing, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 6, 2007
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapyE Van Cutsem, S Siena, Y Humblet, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 23, 2020
The predictive and prognostic significance of cell-free DNA concentration in melanomaR Váraljai, S Elouali, S S Lueong, et al.
European Journal of Cancer (Oxford, England : 1990)|October 24, 2008
MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastomaJ Sadones, A Michotte, P Veld, et al.
ESMO Open|February 15, 2025
Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028M Donia, H Jespersen, M Jalving, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 28, 2022
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142T André, S Lonardi, K Y M Wong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2021
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006G V Long, A Arance, L Mortier, et al.
Pageof 5